MX2009005462A - Analogos de 7,8-saturados-4,5-epoxi-morfinano. - Google Patents

Analogos de 7,8-saturados-4,5-epoxi-morfinano.

Info

Publication number
MX2009005462A
MX2009005462A MX2009005462A MX2009005462A MX2009005462A MX 2009005462 A MX2009005462 A MX 2009005462A MX 2009005462 A MX2009005462 A MX 2009005462A MX 2009005462 A MX2009005462 A MX 2009005462A MX 2009005462 A MX2009005462 A MX 2009005462A
Authority
MX
Mexico
Prior art keywords
epoxy
saturated
morphinanium analogs
morphinanium
analogs
Prior art date
Application number
MX2009005462A
Other languages
English (en)
Inventor
Amy Qi Han
Julio Perez
Yakov Rotshteyn
Original Assignee
Progenics Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc filed Critical Progenics Pharm Inc
Publication of MX2009005462A publication Critical patent/MX2009005462A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Se describen análogos 7,8-saturados de 4,5-epoximorfinano novedosos. También se describen composiciones farmacéuticas que contienen los análogos 7,8- saturados de 4,5-epoxi-mofinano y métodos de sus usos farmacéuticos. Los compuestos descritos son útiles, inter alia, como moduladores de los receptores opioides.
MX2009005462A 2006-11-22 2007-11-21 Analogos de 7,8-saturados-4,5-epoxi-morfinano. MX2009005462A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86709906P 2006-11-22 2006-11-22
US86739006P 2006-11-27 2006-11-27
PCT/US2007/085461 WO2008064353A2 (en) 2006-11-22 2007-11-21 7,8-saturated-4,5-epoxy-morphinanium analogs

Publications (1)

Publication Number Publication Date
MX2009005462A true MX2009005462A (es) 2009-08-28

Family

ID=39430613

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009005455A MX2009005455A (es) 2006-11-22 2007-11-21 (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
MX2009005462A MX2009005462A (es) 2006-11-22 2007-11-21 Analogos de 7,8-saturados-4,5-epoxi-morfinano.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009005455A MX2009005455A (es) 2006-11-22 2007-11-21 (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.

Country Status (8)

Country Link
US (2) US20090047279A1 (es)
EP (2) EP2101773A2 (es)
JP (2) JP2010510328A (es)
AU (2) AU2007323571A1 (es)
BR (1) BRPI0719305A2 (es)
CA (2) CA2670382A1 (es)
MX (2) MX2009005455A (es)
WO (2) WO2008064353A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TW200815451A (en) 2006-08-04 2008-04-01 Wyeth Corp 6-carboxy-normorphinan derivatives, synthesis and uses thereof
AU2008223328B2 (en) * 2007-03-06 2012-10-11 SpecGx LLC Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
MX351611B (es) 2007-03-29 2017-10-20 Wyeth Llc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
CA2682125C (en) 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
DK2139890T3 (da) 2007-03-29 2014-08-25 Wyeth Llc Perifere opioidreceptor-antagonister og anvendelser deraf
CN101959892B (zh) 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US8877524B2 (en) * 2008-03-31 2014-11-04 Cree, Inc. Emission tuning methods and devices fabricated utilizing methods
CN101607963B (zh) * 2008-06-20 2013-04-03 重庆医药工业研究院有限责任公司 吗啡喃衍生物及其制备方法
GB0814043D0 (en) * 2008-07-31 2008-09-10 Serentis Ltd The treatment of skin disorders
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2010096791A1 (en) * 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
CN102325777B (zh) * 2009-02-23 2015-08-12 马林克罗特公司 (+)-吗啡喃*n-氧化物及其制备方法
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
JP5784507B2 (ja) * 2009-02-23 2015-09-24 マリンクロッド エルエルシー （＋）−モルフィナニウム第四級塩およびその生成方法
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
AU2011263416B2 (en) 2010-06-11 2014-04-10 Rhodes Technologies Process for N-dealkylation of tertiary amines
TWI478928B (zh) 2010-06-11 2015-04-01 Rhodes Technologies 用於製備ｎ－烯丙基化合物之過渡金屬催化的製程及其用途
AU2012217903A1 (en) * 2011-02-14 2013-08-15 Alkermes, Inc. Peripherially acting mu opioid antagonists
BR112013027976A2 (pt) * 2011-05-02 2016-08-09 Univ Brock processos e intermediários na preparação de análogos de morfina através da n-desmetilação dos n-óxidos utilizando os reagentes de ciclodesidratação
WO2012166891A2 (en) * 2011-05-31 2012-12-06 Algynomics Inc. Mu-opioid receptor binding compounds
RU2014112493A (ru) 2011-09-08 2015-10-20 МАЛЛИНКРОДТ Эл-Эл-Си Получения алкалоидов без выделения промежуточных продуктов
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
EP2941430B1 (en) * 2012-12-28 2017-04-26 Purdue Pharma LP 7,8-cyclicmorphinan analogs
ES2784690T3 (es) 2013-12-05 2020-09-29 Univ Bath Nuevos compuestos opioides y sus usos
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9701687B2 (en) * 2014-05-05 2017-07-11 Noramco, Inc. Process for the preparation of opioid compounds
US9701688B2 (en) 2014-05-05 2017-07-11 Noramco, Inc. Process for the preparation of opioid compounds
CN105985348B (zh) * 2015-02-12 2019-02-01 正大天晴药业集团股份有限公司 一种溴甲基纳曲酮的制备方法
WO2020023486A1 (en) 2018-07-23 2020-01-30 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
KR20210057132A (ko) * 2018-09-14 2021-05-20 케러 테라퓨틱스, 인코포레이티드 카파 오피오이드 수용체 효능제의 경구 제형
WO2021152113A1 (en) 2020-01-31 2021-08-05 Bayer Aktiengesellschaft Substituted 2,3-benzodiazepines derivatives

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3217006A (en) * 1965-11-09 Purification of d-j-methoxy-n-methyl-ar morphinan
US2813097A (en) * 1955-08-16 1957-11-12 Upjohn Co 3-hydroxy-n-methylmorphinan-n-oxide
US2813098A (en) * 1955-08-16 1957-11-12 Upjohn Co 3-methoxy-n-methylmorphinan n-oxide
US3131185A (en) * 1959-03-18 1964-04-28 Orsymonde Nicotinic esters of hydroxyl derivatives of the phenanthrenic alkaloids of opium, and process for the preparation of these esters
DE1420015B1 (de) * 1959-10-16 1971-08-26 Boehringer Sohn Ingelheim 2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane
US3144459A (en) * 1962-08-06 1964-08-11 Shionogi & Co D-3-methoxy-4-phenoxy-nu-methyl-delta6-morphinan, derivatives thereof, and method for the purification thereof
BE638369A (es) * 1962-10-10
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4990617A (en) * 1985-12-02 1991-02-05 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans and derivatives
US4730048A (en) * 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5434171A (en) * 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5804595A (en) * 1995-12-05 1998-09-08 Regents Of The University Of Minnesota Kappa opioid receptor agonists
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
EP1206264A2 (en) * 1999-08-25 2002-05-22 Barrett R. Cooper Compositions and methods for treating opiate intolerance
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
CA2449175A1 (en) * 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
US7056500B2 (en) * 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
JP4806190B2 (ja) * 2002-09-25 2011-11-02 ユーロ−セルティーク エス．エイ． Ｎ−置換ヒドロモルホン及びそれらの使用
PT1562953E (pt) * 2002-11-08 2009-11-19 Mallinckrodt Inc Processo para a preparação de sais quaternários de n -alquilmorfinano
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos

Also Published As

Publication number Publication date
AU2007323573A1 (en) 2008-05-29
JP2010510329A (ja) 2010-04-02
WO2008064353A2 (en) 2008-05-29
BRPI0719305A2 (pt) 2014-02-04
US20080176884A1 (en) 2008-07-24
US20090047279A1 (en) 2009-02-19
MX2009005455A (es) 2009-08-28
EP2101773A2 (en) 2009-09-23
EP2101774A2 (en) 2009-09-23
CA2670136A1 (en) 2008-05-29
AU2007323571A1 (en) 2008-05-29
WO2008064351A3 (en) 2008-11-20
CA2670382A1 (en) 2008-05-29
WO2008064353A3 (en) 2008-11-27
JP2010510328A (ja) 2010-04-02
WO2008064351A2 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
MX2009005461A (es) N-oxidos de analogos de 4,5-epoxi-morfinano.
WO2006034039A3 (en) Substituted morphinans and methods of their use
HK1120442A1 (en) Novel opioid antagonists
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MY153915A (en) Organic compounds
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
IN2012DN02984A (es)
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
TW200612892A (en) Novel compounds
UA94749C2 (en) Benzimidazole modulators of vr1
MX2009005460A (es) (s)-n-estereoisomeros de analogos de 7,8-saturados-4,5-epoxi-morfi nano.
JO2578B1 (en) Compounds Theophene benzimidazole
TW200738659A (en) Novel compounds
WO2009132313A3 (en) Morphinan derivatives of organic and inorganic acids
TW200745122A (en) New compounds I
MX2009010552A (es) Antagonistas de receptor de opioide periferico y usos de los mismos.
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
HK1154777A1 (en) Lipoprotein lipase-activating compositions comprising benzene derivatives
TW200738649A (en) Calcilytic compounds
SG158091A1 (en) Imidazoazepinone compounds
MX2007006042A (es) Bengamidas que poseen un ciclo caprolactama sustituido, procedimiento de preparacion, composiciones que las contienen y utilizacion.
UA97965C2 (ru) Замещенные пиразолы, содержащая их композиция, способ их получения и применения
MX2009008028A (es) Agentes antiparasitarios.